Hongchao Qi, Angela M Wood, Stephen Kaptoge, Amy McMahon, Susan Mehenny, Nathalie Kingston, Willem H Ouwehand, John Danesh, David J Roberts, Emanuele Di Angelantonio, Lois G Kim
{"title":"Expected outcomes of stratified post-donation testing in whole blood donation in England: A discrete event simulation modeling study.","authors":"Hongchao Qi, Angela M Wood, Stephen Kaptoge, Amy McMahon, Susan Mehenny, Nathalie Kingston, Willem H Ouwehand, John Danesh, David J Roberts, Emanuele Di Angelantonio, Lois G Kim","doi":"10.1111/trf.18165","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In England, blood donors with low hemoglobin concentration are deferred following on-session testing to prevent donations below regulatory thresholds, thereby protecting donors' health and blood supply quality. However, deferrals are costly, time-consuming and may discourage donors. Post-donation testing (PDT), where hemoglobin levels are measured after donation, offer potential alternatives as used in some European countries.</p><p><strong>Study design and methods: </strong>We compared four PDT strategies to the current approach: (A) no on-session testing, (B) on-session testing if low hemoglobin at previous visit, (C) on-session testing if low/medium hemoglobin at previous visit, all with delayed reinvitation if low hemoglobin at previous donation, and (D) on-session testing if low/medium hemoglobin at previous visit without delayed reinvitations. We employed discrete event simulation modeling, informed by data collected from 16,941 donors returning under the current strategy in England, to simulate and compare total donations, under-threshold donations, and deferrals for each strategy over 18 months.</p><p><strong>Results: </strong>Strategy A eliminated deferrals but led to increased under-threshold donations compared to the current strategy in men (6.5% vs. 2.3%) and women (11.8% vs. 4.5%). Strategies B-D reduced deferrals rates for men (1.0%-3.7% vs. 5.5%) and women (2.2%-6.3% vs. 8.9%) but showed slightly higher under-threshold donations in men (3.0%-5.1% vs. 2.3%) and women (5.3%-8.8% vs. 4.5%). Strategies with more on-session testing had lower under-threshold donations.</p><p><strong>Discussion: </strong>PDT strategies incorporating on-session testing for low/medium hemoglobin at previous visits could reduce deferrals while maintaining a low proportion of under-threshold donations, thereby balancing donor safety with operational efficiency.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"696-707"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005575/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.18165","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In England, blood donors with low hemoglobin concentration are deferred following on-session testing to prevent donations below regulatory thresholds, thereby protecting donors' health and blood supply quality. However, deferrals are costly, time-consuming and may discourage donors. Post-donation testing (PDT), where hemoglobin levels are measured after donation, offer potential alternatives as used in some European countries.
Study design and methods: We compared four PDT strategies to the current approach: (A) no on-session testing, (B) on-session testing if low hemoglobin at previous visit, (C) on-session testing if low/medium hemoglobin at previous visit, all with delayed reinvitation if low hemoglobin at previous donation, and (D) on-session testing if low/medium hemoglobin at previous visit without delayed reinvitations. We employed discrete event simulation modeling, informed by data collected from 16,941 donors returning under the current strategy in England, to simulate and compare total donations, under-threshold donations, and deferrals for each strategy over 18 months.
Results: Strategy A eliminated deferrals but led to increased under-threshold donations compared to the current strategy in men (6.5% vs. 2.3%) and women (11.8% vs. 4.5%). Strategies B-D reduced deferrals rates for men (1.0%-3.7% vs. 5.5%) and women (2.2%-6.3% vs. 8.9%) but showed slightly higher under-threshold donations in men (3.0%-5.1% vs. 2.3%) and women (5.3%-8.8% vs. 4.5%). Strategies with more on-session testing had lower under-threshold donations.
Discussion: PDT strategies incorporating on-session testing for low/medium hemoglobin at previous visits could reduce deferrals while maintaining a low proportion of under-threshold donations, thereby balancing donor safety with operational efficiency.
背景:在英国,血红蛋白浓度低的献血者被推迟进行现场检测,以防止低于规定阈值的献血者,从而保护献血者的健康和血液供应质量。但是,延期支付费用高、耗时长,而且可能使捐助者泄气。捐献后检测(PDT),即在捐献后测量血红蛋白水平,提供了一些欧洲国家使用的潜在替代方法。研究设计和方法:我们将四种PDT策略与目前的方法进行了比较:(A)不进行现场检测,(B)之前就诊时是否有低血红蛋白的现场检测,(C)之前就诊时是否有低/中血红蛋白的现场检测,如果之前献血时血红蛋白低,则延迟再次邀请,(D)之前就诊时是否有低/中血红蛋白的现场检测,没有延迟再次邀请。我们采用离散事件模拟模型,根据从英国现行策略下返回的16,941名捐赠者收集的数据,模拟和比较每种策略在18个月内的总捐赠、阈值以下捐赠和延迟捐赠。结果:策略A消除了延迟,但与当前策略相比,男性(6.5%对2.3%)和女性(11.8%对4.5%)的阈下捐赠增加。B-D策略降低了男性(1.0%-3.7% vs. 5.5%)和女性(2.2%-6.3% vs. 8.9%)的延迟捐赠率,但男性(3.0%-5.1% vs. 2.3%)和女性(5.3%-8.8% vs. 4.5%)的阈值以下捐赠率略高。有更多的会话测试的策略有更低的阈下捐赠。讨论:PDT策略包括在先前就诊时进行低/中血红蛋白的现场检测,可以减少延迟,同时保持低比例的低于阈值的捐献,从而平衡献血者安全和操作效率。
期刊介绍:
TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.